KINTOR PHARMA-B (09939) plans to discount approximately 15.03% to issue 30.4875 million subscribing shares, raising approximately HK$49.78 million net.

KINTOR PHARMA-B (09939) announced that on November 12, 2025, the company intends to issue 30.4875 million shares of subscription shares to HuaYuan Management Consulting (Hong Kong) Limited, a wholly-owned subsidiary of China-Singapore Suzhou Industrial Park Venture Investment Co., Ltd., at a subscription price of HK$1.64 per share, representing a discount of approximately 15.03% compared to the closing price of HK$1.93 per share on the last trading day on the Stock Exchange. The net proceeds from the subscription amount to approximately HK$49.78 million, intended to be used for general operating capital for the group's daily business as well as for the Phase III clinical trial of KX-826.